The U.S. Patent and Trademark Office will be holding its next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting, as a virtual meeting, on March 29, 2022. The agenda for the meeting is as follows:
• Welcoming and Opening Remarks (9:00 - 9:10 am ET) -- Daniel Sullivan and Gary Jones, Directors, TC1600, USPTO
• Claim Construction and Doctrine of Equivalents -- A review for the Patent Office (9:10 - 10:30 am) -- Henry C. Su, Bradley Arant Boult Cummings LLP
Break (10:30 – 10:40 am)
• Statutory provisions governing patent infringement -- A practical analysis (10:40 - 11:40 am) -- Christopher J. Harnett, Maynard, Cooper & Gale
• Deferred subject matter eligibility response (DSMER) pilot program (11:40 am - 12:00 pm) -- Daniel Kolker, Supervisory Patent Examiner (SPE), TC1600, USPTO
• Lunch (12:00 – 1:00 pm)
• Patent Quality Metrics (1:00 - 1:30 pm) -- Kathleen Bragdon, Quality Assurance Specialist (mQAS), OPQA, USPTO
• Providing explicit rationales in rejections under 35 U.S.C. 103 (1:30 - 2:30 pm) -- Lora Barnhart Driscoll, Quality Assurance Specialist (TQAS), TC1600, USPTO
• Break (2:30 – 2:40 pm)
• Biological Sequence Searching (2:40 - 3:10 pm) -- Christopher Babic, Supervisory Patent Examiner (SPE), TC1600, USPTO
• A systematic approach to 35 U.S.C. 112(b) (3:10 – 4:40 pm) -- Gary Benzion, Supervisory Patent Examiner (SPE); Bennett Celsa, Quality Assurance Specialist (TQAS); Amjad Abraham, Supervisory Patent Examiner (SPE); Ashwin Mehta, Review Quality Assurance Specialist (RQAS) -- TC1600 and OPQA, USPTO
• Closing Remarks (4:40 - 5:00 pm) -- Directors, TC1600, USPTO
Additional information regarding the BCP customer partnership meeting, including registration information for those wishing to attend the meeting or register for online participation, can be found here. The agenda for the BCP customer partnership meeting can be found here.
Comments